BlackRock’s Alzamend Neuro ALZN Stock Holding History

BlackRock’s Portfolio ALZN Stock Details ALZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$524	Hold	437	–	–	﹤0.01%	5580
2026 Q1	$463	Hold	437	–	–	﹤0.01%	5575
2025 Q4	$795	Hold	437	–	–	﹤0.01%	5431
2025 Q3	$1.04K	Sell	437 -4	-0.9%	-$10	﹤0.01%	5348
2025 Q2	$1.28K	Hold	441	–	–	﹤0.01%	5343
2025 Q1	$3.77K	Hold	441	–	–	﹤0.01%	5262
2024 Q4	$4.61K	Hold	441	–	–	﹤0.01%	5227
2024 Q3	$6.71K	Sell	441 -1	-0.2%	-$26	﹤0.01%	5019
2024 Q2	$15.7K	Hold	442	–	–	﹤0.01%	5033
2024 Q1	$39.7K	Hold	442	–	–	﹤0.01%	4920
2023 Q4	$35.4K	Hold	442	–	–	﹤0.01%	5018
2023 Q3	$141K	Hold	442	–	–	﹤0.01%	4764
2023 Q2	$304K	Hold	442	–	–	﹤0.01%	4624
2023 Q1	$253K	Hold	442	–	–	﹤0.01%	4712
2022 Q4	$337K	Hold	442	–	–	﹤0.01%	4711
2022 Q3	$709K	Buy	+442	New	+$607K	﹤0.01%	4611

Other funds holding ALZN

KWM

KMT Wealth Management El Segundo, California $118M AUM 26.19% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

HIA

Harbor Investment Advisory Lutherville, Maryland $1.43B AUM 30.71% 1-Year Est. Return

BlackRock's ALZN Position: Q2 2026 in Review

BlackRock held its Alzamend Neuro (ALZN) position steady in Q2 2026 at 437 shares worth $524. The position accounts for ﹤0.01% of the portfolio, ranked #5580.

BlackRock first reported a position in ALZN in Q3 2022 and has held it in 16 quarters since. The position peaked at $709K in Q3 2022. 5 funds tracked by Wall St. Rank hold ALZN as of Q2 2026.

BlackRock held 437 shares of Alzamend Neuro worth $524 as of Q2 2026.
BlackRock left its Alzamend Neuro share count unchanged in Q2 2026.
Alzamend Neuro made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #5580 holding.
BlackRock first reported a position in Alzamend Neuro in Q3 2022 and has held it in 16 quarters since.
BlackRock's Alzamend Neuro position peaked at $709K in Q3 2022.
5 funds tracked by Wall St. Rank held Alzamend Neuro as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.